VCYT Q2 2022 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M+32.2% YoY

Gross Profit

$48M65.6% margin

Operating Income

-$11M-14.7% margin

Net Income

-$10M-13.1% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

-$363,000

Free Cash Flow

-$3M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$80M

Stockholders' Equity

$1.1B

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$55M	+32.2%
Gross Profit	$48M	$38M	+27.1%
Operating Income	-$11M	-$7M	-43.6%
Net Income	-$10M	-$9M	-5.5%

Revenue Segments

Testing

$60M82%

Biopharmaceutical And Other

$10M14%

Product

$3M4%